Envestnet Asset Management
IDNA icon

Envestnet Asset Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Envestnet Asset Management’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Buy
20,129
+7,738
+62% +$232K ﹤0.01% 3877
2026
Q1 		$360K Buy
12,391
+2,993
+32% +$86.9K ﹤0.01% 4164
2025
Q4 		$246K Buy
+9,398
New +$242K ﹤0.01% 4146
2024
Q1 		– Sell
-26,270
Closed -$604K – 4226
2023
Q4 		$604K Buy
26,270
+588
+2% +$11.8K ﹤0.01% 3231
2023
Q3 		$523K Sell
25,682
-1,200
-4% -$26.9K ﹤0.01% 3226
2023
Q2 		$628K Sell
26,882
-578
-2% -$13.9K ﹤0.01% 3087
2023
Q1 		$639K Buy
27,460
+4,676
+21% +$117K ﹤0.01% 2985
2022
Q4 		$573K Buy
+22,784
New +$612K ﹤0.01% 3024

Other funds holding IDNA

AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PCA
Prosperity Capital Advisors Westlake, Ohio $2.03B AUM 23.67% 1-Year Est. Return
FHC
First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return
M
MATAURO New York $756M AUM 20.74% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Envestnet Asset Management's IDNA Position: Q2 2026 in Review

Envestnet Asset Management increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 62% in Q2 2026, buying an estimated $232K and bringing the position to 20,129 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #3877.

Envestnet Asset Management first reported a position in IDNA in Q4 2022 and has held it in 8 quarters since. 26 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

  • Envestnet Asset Management held 20,129 shares of iShares Genomics Immunology and Healthcare ETF worth $679K as of Q2 2026.
  • Envestnet Asset Management bought 7,738 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $232K.
  • iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3877 holding.
  • Envestnet Asset Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2022 and has held it in 8 quarters since.
  • 26 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.